Liver cancer carries a five-year survival of 21.7%,1 and for the fifth of patients diagnosed after it has spread, 3.3%.

The best first-line therapy available reaches a median of nineteen months.2

With a highly relevant target structure first appearing in late 2025, there is now a solvable problem standing between patients and a therapy.

Please note: Andovar Bioworks operates in a stealth capacity.

Messages arrive with the people doing the work. We keep your details for correspondence and no other purpose. Privacy.